Get quick answers to your questions about the article from our AI researcher chatbot
{'id': 'https://openalex.org/W2749169318', 'doi': None, 'title': 'これからの免疫療法の話をしよう 第4回 抗PD‐L1抗体療法―atezolizumab,durvalumab,avelumab', 'display_name': 'これからの免疫療法の話をしよう 第4回 抗PD‐L1抗体療法―atezolizumab,durvalumab,avelumab', 'publication_year': 2017, 'publication_date': '2017-01-01', 'ids': {'openalex': 'https://openalex.org/W2749169318', 'mag': '2749169318'}, 'language': 'et', 'primary_location': {'is_oa': False, 'landing_page_url': 'http://jglobal.jst.go.jp/public/201702222445457535', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S2764778903', 'display_name': 'Cancer board square', 'issn_l': '2189-6429', 'issn': ['2189-6429'], 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': None, 'host_organization_name': None, 'host_organization_lineage': [], 'host_organization_lineage_names': [], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': [], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5004083171', 'display_name': '北野滋久', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': True, 'raw_author_name': '北野滋久', 'raw_affiliation_strings': [], 'affiliations': []}], 'institution_assertions': [], 'countries_distinct_count': 0, 'institutions_distinct_count': 0, 'corresponding_author_ids': ['https://openalex.org/A5004083171'], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 64}, 'biblio': {'volume': '3', 'issue': '1', 'first_page': '140', 'last_page': None}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy', 'score': 0.9891, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy', 'score': 0.9891, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/atezolizumab', 'display_name': 'Atezolizumab', 'score': 0.9762043}, {'id': 'https://openalex.org/keywords/durvalumab', 'display_name': 'Durvalumab', 'score': 0.9734553}, {'id': 'https://openalex.org/keywords/avelumab', 'display_name': 'Avelumab', 'score': 0.9449177}, {'id': 'https://openalex.org/keywords/pd-1-and-pd-l1', 'display_name': 'PD-1 and PD-L1', 'score': 0.628931}], 'concepts': [{'id': 'https://openalex.org/C2775949291', 'wikidata': 'https://www.wikidata.org/wiki/Q20707748', 'display_name': 'Atezolizumab', 'level': 5, 'score': 0.9762043}, {'id': 'https://openalex.org/C2777742743', 'wikidata': 'https://www.wikidata.org/wiki/Q19904005', 'display_name': 'Durvalumab', 'level': 5, 'score': 0.9734553}, {'id': 'https://openalex.org/C2777381376', 'wikidata': 'https://www.wikidata.org/wiki/Q21083261', 'display_name': 'Avelumab', 'level': 5, 'score': 0.9449177}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.31794906}, {'id': 'https://openalex.org/C2780030458', 'wikidata': 'https://www.wikidata.org/wiki/Q7041828', 'display_name': 'Nivolumab', 'level': 4, 'score': 0.2609609}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.13851711}, {'id': 'https://openalex.org/C2777701055', 'wikidata': 'https://www.wikidata.org/wiki/Q1427096', 'display_name': 'Immunotherapy', 'level': 3, 'score': 0.08850017}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.071410894}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'http://jglobal.jst.go.jp/public/201702222445457535', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S2764778903', 'display_name': 'Cancer board square', 'issn_l': '2189-6429', 'issn': ['2189-6429'], 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': None, 'host_organization_name': None, 'host_organization_lineage': [], 'host_organization_lineage_names': [], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': [], 'abstract_inverted_index': None, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2749169318', 'counts_by_year': [], 'updated_date': '2024-09-19T17:58:45.694280', 'created_date': '2017-08-31'}